8-K Announcements
6Material company update
Apr 22, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Oct 24, 2025·SEC
NeurAxis, Inc.(NRXS)Earnings, Financials & Key Ratios
NRXS•NASDAQ
$7.16
Price updated Jul 6, 2026
AboutNeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.Show more
- Revenue$4M+32.9%
- EBITDA-$8M-9.2%
- Net Income-$8M+5.4%
- EPS (Diluted)-0.95+22.1%
- Gross Margin84.23%-2.7%
- EBITDA Margin-217.7%+17.9%
- Operating Margin-219.37%+17.7%
- Net Margin-218.55%+28.8%
- ROE-285.36%+88.5%
NRXS Price & Volume
NeurAxis, Inc. (NRXS) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Revenue Growth Faces Liquidity Sustainability Hurdles
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Accelerating
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and capital dependency
Key Thesis Takeaways
- NeurAxis is currently navigating a critical commercial expansion phase for its IB-Stim device, evidenced by a 79.5% year-over-year revenue growth rate in 2026Q1.
- While the company maintains high gross margins of 86.4%, the lack of operational leverage, reflected in a -108.3% operating margin, necessitates a transition toward self-sustaining cash flows.
- Investors should monitor the company's $7.1 million cash position against persistent negative free cash flow to assess the risk of future dilutive financing requirements.
Verdict Logic
the company's persistent cash burn and lack of positive free cash flow, coupled with an operating margin of -108.3%, suggest significant liquidity risks that outweigh the current 79.5% revenue growth trajectory.
NRXS Growth Metrics
NeurAxis, Inc. (NRXS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years13.08%
3 Years9.96%
TTM45.88%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM13.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM35.48%
Return on Capital
10 Years-634.24%
5 Years-768.52%
3 Years-886.78%
Last Year-263.8%
NRXS Recent Earnings
NeurAxis, Inc. (NRXS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (40%)●Beat Revenue 2/12 qtrs (67%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.18+5.3%
$0.19
Rev
$2M+10.9%
$1M
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.17+20.9%
$0.21
Rev
$968,000+13.9%
$850,000
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.24
—
Rev
$811,414
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.22
—
Rev
$894,086
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.18vs $0.19+5.3% | $2Mvs $1M+10.9% |
| Q2 2026 | Mar 19, 2026 | $0.17vs $0.21+20.9% | $968,000vs $850,000+13.9% |
| Q4 2025 | Nov 10, 2025 | $0.24 | $811,414 |
| Q3 2025 | Aug 12, 2025 | $0.22 | $894,086 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for NeurAxis, Inc. (NRXS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.16 | $88.67M | -7.54 | 32.89% | -218.55% | -285.36% | — | |
| $84.03 | $4.62B | -18.88 | 10.74% | 7.47% | 9.13% | — | |
| $46.31 | $383.45M | 53.85 | 16.97% | 14.08% | 22.14% | — | |
| $1.35 | $93.94M | -2.29 | 99.17% | -24.48% | -139.83% | — | |
| $83.06 | $106.64B | 22.27 | 8.43% | 13.2% | 9.78% | — | |
| $95.63 | $166.57B | 25.71 | 5.67% | 13.91% | 12.09% | — |
Compare NRXS vs Peers
NeurAxis, Inc. (NRXS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NRXS SEC Filings & Documents
NeurAxis, Inc. (NRXS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when NRXS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NRXS Frequently Asked Questions
NeurAxis, Inc. (NRXS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is NeurAxis, Inc.'s revenue?
NeurAxis, Inc. (NRXS) reported $4.3M in revenue for fiscal year 2025. This represents a 122% increase from $1.9M in 2020.
How fast is NeurAxis, Inc. growing?
NeurAxis, Inc. (NRXS) grew revenue by 32.9% over the past year. This is strong growth.
Is NRXS profitable?
NeurAxis, Inc. (NRXS) reported a net loss of $7.3M for fiscal year 2025.
Dividend & Returns
What is NRXS's return on equity?
NeurAxis, Inc. (NRXS) has a return on equity (ROE) of -285.4%. Negative ROE indicates the company is unprofitable.
What is NeurAxis, Inc.'s free cash flow?
NeurAxis, Inc. (NRXS) had negative free cash flow of $6.1M in fiscal year 2025, likely due to heavy capital investments.